HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Clinical trials for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS trials appear
Sign up with your email to follow new studies for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug targets tough lymphomas in early trial
Disease control Recruiting nowThis early-phase trial tests a drug called pidnarulex (CX-5461) in about 50 people with aggressive B-cell lymphomas that have not responded to standard treatments. The goal is to find the best dose and check if the drug is safe and can shrink tumors. Participants will also have b…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 23, 2026 16:46 UTC
-
New cocktail aims to knock out tough lymphoma
Disease control Recruiting nowThis early-phase trial is testing whether adding the targeted drug polatuzumab vedotin (with or without another drug called glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to se…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 23, 2026 12:09 UTC
-
New Two-Step attack on aggressive lymphoma shows promise in early trial
Disease control Recruiting nowThis phase 2 trial is testing whether a targeted antibody-drug combination (loncastuximab tesirine plus rituximab) followed by standard chemotherapy can improve outcomes for people with high-risk diffuse large B-cell lymphoma. The study enrolls 24 adults with untreated double-exp…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
New Dual-Target CAR-T therapy offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests a new treatment called C-CAR039 (Prizlon-cel) for people with large B-cell lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified to attack two targets on cancer cells. The goal is to find the saf…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE1, PHASE2 • Sponsor: Shanghai AbelZeta Ltd. • Aim: Disease control
Last updated Jun 22, 2026 12:04 UTC
-
New combo may boost CAR-T success in tough lymphoma
Disease control Recruiting nowThis study tests whether giving two drugs (loncastuximab tesirine and rituximab) before standard CAR-T cell therapy can improve outcomes for adults with large B-cell lymphoma that has come back or not responded to treatment. About 29 participants will receive this bridging therap…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 22, 2026 12:04 UTC
-
New combo therapy shows promise for tough lymphoma
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy (EPOCH-R) is safe and effective for people with aggressive B-cell non-Hodgkin lymphoma. About 18 participants will receive the combination as their first treatment. The goal is to see if the new combo c…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 22, 2026 11:54 UTC
-
New combo therapy offers hope for Hard-to-Treat leukemia
Disease control Recruiting nowThis study combines a targeted antibody-drug (inotuzumab ozogamicin) with low-intensity chemotherapy to treat adults with acute lymphoblastic leukemia (ALL). The goal is to find the best dose and see if the combination improves survival and remission rates. Participants include o…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
Hope for lymphoma patients: new drug cocktail targets resistant cancer
Disease control Recruiting nowThis study tests whether adding either tazemetostat or zanubrutinib to a standard two-drug therapy (tafasitamab and lenalidomide) can shrink tumors or delay cancer return in people with large B-cell lymphoma that came back or didn't respond to prior treatment. About 227 adults wh…
Matched conditions: HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 08, 2026 13:12 UTC